Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 176   

Articles published

SNY 42.43 +0.32 (0.76%)
price chart
Pfizer Inc, Sanofi SA (ADR) Could Eye Biogen's Hemophilia Franchise
Sanofi SA (ADR) could be one of the potential buyers interested in paying up for Biogen's hemophilia business. Having no approved and launched drugs for the treatment of the rare blood disorder, Sanofi might be interested in investigating a potential ...
Sanofi SA May Raise its Medivation Inc Bid “Considerably”: Credit Suisse
Medivation Inc. (NASDAQ:MDVN) has designated June 1 as the record date for its shareholders to vote on Sanofi SA's (ADR) (NYSE:SNY) proposal to oust the cancer company's board of directors. After Medivation rejected Sanofi's $9.3 billion takeover offer ...
Sanofi SA (ADR) (SNY) Working With U.S. Army to Combat Zika Virus
Sanofi SA (ADR) (SNY) Working With U.S. Army to Combat Zika Virus. It's the only company developing a Zika vaccine.
Who Will Acquire Medivation Inc; Sanofi SA (ADR), Gilead Sciences, Inc. or Others?
On the other hand, Sanofi SA (NYSE:SNY) is also working with the financial advisers for a possible acquisition of the Medivation.
Medivation Surges On Reported Pushback Of Sanofi Takeover Effort  Benzinga
M&A Buzz Sets Medivation Inc (MDVN) Options Pits on Fire  Schaeffers Research (blog)
Sanofi SA Achieves Another Milestone in Diabetes Treatment
Sanofi SA (ADR) (NYSE:SNY) announced on Sunday that its diabetes drug LixiLan met its endpoints in two late-stage clinical studies, dubbed as LixiLan-O and LixiLan-L.
Sanofi, Regeneron Pharmaceuticals Inc. To Launch Blockbuster Molecule Really Soon
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in collaboration with Sanofi (NYSE:SNY) has announced the positive results in relation to the clinical trials of the investigational molecule dupilumab indicated for the management and treatment rare skin ...
Sanofi SA (ADR) on Focus After Raising In Today's Session
The stock of Sanofi SA (ADR) (NYSE:SNY) is a huge mover today! About 628,023 shares traded hands. Sanofi SA (ADR) (NYSE:SNY) has declined 2.42% since December 15, 2015 and is downtrending. It has underperformed by 8.38% the S&P500.
Medivation Inc Shareholders May Turn Down Sanofi's Bid
Medivation Inc (NASDAQ:MDVN), the most attractive acquisition target for large drug makers seeking high growth assets specifically in the area of oncology, faces a crucial decision at this point as Sanofi SA (ADR) (NYSE:SNY) advances with its takeover ...
GlaxoSmithKline PLC (ADR) (GSK) Poised To Overtake Sanofi SA (ADR) (SNY) In ...
GlaxoSmithKline PLC (ADR) (NYSE:GSK) is on the verge of leapfrogging Sanofi SA (ADR) (NYSE:SNY) in the meningococcal vaccine market in terms of sales.
Sanofi SA (ADR) Draws Bullish Attention After Its Gap Up Today
The stock of Sanofi SA (ADR) (NYSE:SNY) gapped up by $0.31 today and has $66.19 target or 58.00% above today's $41.89 share price.